Witzens-Harig M - Search Results

1

Cellular Immunotherapy in B-Cell Malignancy.

Schwarzbich MA, Witzens-Harig M. Schwarzbich MA, et al. Oncol Res Treat. 2017;40(11):674-681. doi: 10.1159/000481946. Epub 2017 Oct 20. Oncol Res Treat. 2017. PMID: 29065420 Review.

2

Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era.

Lehners N, Krämer I, Schwarzbich MA, Ho AD, Witzens-Harig M. Lehners N, et al. Leuk Lymphoma. 2016 Nov;57(11):2619-25. doi: 10.3109/10428194.2016.1157869. Epub 2016 Mar 21. Leuk Lymphoma. 2016. PMID: 26999040

3

Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.

Kriegsmann K, Rieger M, Schwarzbich MA, Sitter S, Kriegsmann M, Bruckner T, Hensel M, Ho AD, Witzens-Harig M, Wuchter P. Kriegsmann K, et al. Eur J Haematol. 2018 Jul;101(1):12-20. doi: 10.1111/ejh.13064. Epub 2018 May 17. Eur J Haematol. 2018. PMID: 29575332

4

Ibrutinib.

Charalambous A, Schwarzbich MA, Witzens-Harig M. Charalambous A, et al. Recent Results Cancer Res. 2018;212:133-168. doi: 10.1007/978-3-319-91439-8_7. Recent Results Cancer Res. 2018. PMID: 30069629

5

Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma.

Lisenko K, Cremer M, Schwarzbich MA, Kriegsmann M, Ho AD, Witzens-Harig M, Wuchter P. Lisenko K, et al. Biol Blood Marrow Transplant. 2016 Aug;22(8):1397-1402. doi: 10.1016/j.bbmt.2016.03.030. Epub 2016 Apr 7. Biol Blood Marrow Transplant. 2016. PMID: 27060439 Free article.

6

In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study.

Cremer M, Schwarzbich MA, Schöning T, Lisenko K, Ho AD, Witzens-Harig M. Cremer M, et al. Ann Hematol. 2017 Sep;96(9):1573-1575. doi: 10.1007/s00277-017-3044-4. Epub 2017 Jun 16. Ann Hematol. 2017. PMID: 28623395 No abstract available.

7

NKT cells - New players in CAR cell immunotherapy?

Kriegsmann K, Kriegsmann M, von Bergwelt-Baildon M, Cremer M, Witzens-Harig M. Kriegsmann K, et al. Eur J Haematol. 2018 Dec;101(6):750-757. doi: 10.1111/ejh.13170. Epub 2018 Oct 9. Eur J Haematol. 2018. PMID: 30187578 Review.

8

Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.

Witzens-Harig M, Benner A, McClanahan F, Klemmer J, Brandt J, Brants E, Rieger M, Meissner J, Hensel M, Neben K, Dreger P, Lengfelder E, Schmidt-Wolf I, Krämer A, Ho AD. Witzens-Harig M, et al. Br J Haematol. 2015 Dec;171(5):710-9. doi: 10.1111/bjh.13652. Epub 2015 Oct 9. Br J Haematol. 2015. PMID: 26449739 Free article. Clinical Trial.

9

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.

Angelova AL, Witzens-Harig M, Galabov AS, Rommelaere J. Angelova AL, et al. Front Oncol. 2017 May 12;7:93. doi: 10.3389/fonc.2017.00093. eCollection 2017. Front Oncol. 2017. PMID: 28553616 Free PMC article.

10

Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy.

Brandt J, Dietrich S, Meissner J, Neben K, Ho AD, Witzens-Harig M. Brandt J, et al. Leuk Lymphoma. 2010 Nov;51(11):2012-20. doi: 10.3109/10428194.2010.513749. Epub 2010 Sep 21. Leuk Lymphoma. 2010. PMID: 20858092

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

115 results

Search Page